SynthesisBMC cardiovascular disorders2025
Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in BMC cardiovascular disorders, 2025. The graph read 1 number from its abstract, feeding 1 cell of the map: it supports the treatment in 1. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
There was a significant reduction in the risk of major adverse cardiovascular events (MACE) after administration of semaglutide (RR: 0.81, 95% CI: 0.74-0.88, p < 0.001, I CONCLUSION: Semaglutide effectively reduces the risk of MACE and modestly improves cardiovascular mortality rates and nonfatal myocardial infarction, without significantly affecting nonfatal stroke incidence and hospitalizations (for angina and heart failure).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
GLP-1 receptor agonists×cardiovascular events
SupportsOpen on the map →What to test next →13 readable studies in this cell: 7 favour the treatment, 2 find no difference, 4 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.PLoS medicine · 2026 · on this mapPooled it
- Advances in proteomics research related to semaglutide: evidence from humans and animals.Journal of endocrinological investigation · 2026Review
- Sirtuin 1 deficiency mediates chronic kidney disease-induced inflammaging cardiovascular calcification.Molecular biomedicine · 2026Article
- Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes.Current diabetes reports · 2026Review
- Mitochondrial Homeostasis in Diabetic Cardiomyopathy: From Dysfunction to Therapeutic Strategies.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
backgroundSemaglutide, a GLP-1 receptor agonist (GLP-1RA), has shown potential in controlling type 2 diabetes due to their ability to lower blood glucose and improve cardiovascular outcomes. Although semaglutide is the newest GLP-1RA available, its cardiovascular effects have not yet been systematically reviewed.
methodsThis meta-analysis adhered to a pre-registered protocol (PROSPERO ID: CRD42024538847). PubMed, Scopus, and Web of Science were searched comprehensively on February 26, 2024, to locate randomized controlled trials (RCTs) assessing semaglutide's impact on cardiovascular outcomes. A random effects model was used to analyze the data and the Cochrane risk of bias 2 tool was used to assess the quality of included studies.
resultsThere were four RCTs involving 27,617 individuals (13,809 receiving semaglutide and 13,808 receiving placebo). There was a significant reduction in the risk of major adverse cardiovascular events (MACE) after administration of semaglutide (RR: 0.81, 95% CI: 0.74-0.88, p < 0.001, I
conclusionSemaglutide effectively reduces the risk of MACE and modestly improves cardiovascular mortality rates and nonfatal myocardial infarction, without significantly affecting nonfatal stroke incidence and hospitalizations (for angina and heart failure). While it lowers the occurrence of serious adverse events, it also increases the likelihood of discontinuing treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.